Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer

被引:22
|
作者
Lambertini, Matteo [1 ,2 ]
Del Mastro, Lucia [3 ]
Viglietti, Giulia [2 ]
Ponde, Noam F. [1 ]
Solinas, Cinzia [4 ]
de Azambuja, Evandro [1 ]
机构
[1] Univ Libre Bruxelles, BrEAST Data Ctr, Dept Med, Inst Jules Bordet, Brussels, Belgium
[2] Univ Libre Bruxelles, Breast Canc Translat Res Lab, Inst Jules Bordet, Brussels, Belgium
[3] IRCCS AOU San Martino IST, Dept Med Oncol, UO Sviluppo Terapie Innovat, Genoa, Italy
[4] Univ Libre Bruxelles, Inst Jules Bordet, Mol Immunol Unit, Brussels, Belgium
关键词
Breast cancer; Premenopausal patients; Young patients; Ovarian function suppression; LHRHa; Adjuvant endocrine therapy; Fertility preservation; ADJUVANT ENDOCRINE THERAPY; INTERNATIONAL CONSENSUS GUIDELINES; OOPHORECTOMY PLUS TAMOXIFEN; PATIENT-LEVEL METAANALYSIS; FERTILITY PRESERVATION; HORMONE AGONISTS; YOUNG-WOMEN; CLINICAL-PRACTICE; AMERICAN SOCIETY; ZOLEDRONIC ACID;
D O I
10.1007/s11864-017-0442-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancers arising in young women are biologically more aggressive, and most of these patients are candidates to receive aggressive treatments that include the use of chemotherapy. As most of these tumors express the hormone receptors (i.e., luminal disease), these patients are also candidates to adjuvant endocrine therapy. Chemotherapy-induced amenorrhea showed to be prognostic in young patients with luminal breast cancer. However, the role of ovarian function suppression (OFS) in addition to standard adjuvant treatments has been largely debated over the past years. Recently, several studies have provided important insights on the role of OFS. Currently, the use of tamoxifen alone without prior cytotoxic therapy can be considered a very effective treatment option in young patients with hormone receptor-positive breast cancer at low risk of relapse. On the other hand, for patients at higher risk of relapse as those who are candidates to (neo) adjuvant chemotherapy, OFS proved to be beneficial, and therefore luteinizing hormone-releasing hormone agonists (LHRHa) should be considered in addition to tamoxifen or aromatase inhibitors (AI). However, toxicity is considerable and patients should be actively engaged in decision-making. Finally, in young breast cancer patients who are candidates to (neo) adjuvant chemotherapy, loss of ovarian function and fertility may be a concern. Besides other techniques, recent results showed that temporary OFS with LHRHa during cytotoxic treatment can be considered a reliable strategy to preserve gonadal function and fertility. Despite the recent advances in the field, several gray zones remain unanswered: the role of OFS plus AI in women who remained premenopausal after 5 years of tamoxifen, the optimal extended approach in women treated with 5 years of OFS plus AI, and the role of temporary OFS with LHRHa during chemotherapy in the specific subgroup of patients with BRCA mutations and in women undergoing this strategy after prior embryo/oocyte cryopreservation.
引用
收藏
页数:18
相关论文
共 50 条
  • [11] Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
    Venturelli, Marta
    Guaitoli, Giorgia
    Omarini, Claudia
    Moscetti, Luca
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2018, 10 : 39 - 49
  • [12] Association between duration of ovarian function suppression and overall survival in premenopausal women with early breast cancer
    Altundag, Kadri
    [J]. JOURNAL OF BUON, 2020, 25 (02): : 1267 - 1267
  • [13] Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study
    Ferreira, Arlindo R.
    Ribeiro, Joana
    Miranda, Ana
    Mayer, Alexandra
    Passos-Coelho, Jose Luis
    Brito, Margarida
    Fernandes, Joao
    Gouveia, Joaquim
    Costa, Luis
    Vaz-Luis, Ines
    [J]. CLINICAL BREAST CANCER, 2019, 19 (05) : E654 - E667
  • [14] Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer
    Lambertini, Matteo
    Viglietti, Giulia
    de Azambuja, Evandro
    [J]. CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 43 - 51
  • [15] Ovarian Function Suppression Plus Fulvestrant in Premenopausal Women with Metastatic Breast Cancer
    Bartsch, R.
    Bago-Horvath, Z.
    Pluschnig, U.
    Berghoff, A.
    Dubsky, P.
    Mader, R. M.
    Fitzal, F.
    Gnant, M.
    Zielinski, C. C.
    Steger, G. G.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S54 - S54
  • [16] Role of Ovarian Suppression in Early Premenopausal Breast Cancer
    Francis, Prudence A.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 79 - 88
  • [17] LHRH agonists could benefit premenopausal women with early-stage breast cancer
    不详
    [J]. Nature Clinical Practice Endocrinology & Metabolism, 2009, 5 (2): : 64 - 65
  • [18] Aromatase inhibitors plus ovarian function suppression versus tamoxifen plus ovarian function suppression for premenopausal women with early stage breast cancer: a systematic review and meta-analysis
    Meng, Jiajia
    Wang, Xiaolan
    Guan, Yufu
    Zhang, Dianlong
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (04) : 2294 - 2302
  • [19] Ovarian preservation for premenopausal women with early-stage endometrial cancer: a Chinese retrospective study
    Lyu, Tianjiao
    Guo, Lu
    Chen, Xiaojun
    Jia, Nan
    Gu, Chao
    Zhu, Menghan
    Zhao, Yuqing
    Liu, Xiaoxia
    Feng, Weiwei
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019, 47 (06) : 2492 - 2498
  • [20] Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer
    O'Regan, Ruth M.
    Zhang, Yi
    Fleming, Gini F.
    Francis, Prudence A.
    Kammler, Roswitha
    Viale, Giuseppe
    Dell'Orto, Patrizia
    Lang, Istvan
    Bellet, Meritxell
    Bonnefoi, Herve R.
    Tondini, Carlo
    Villa, Federica
    Bernardo, Antonio
    Ciruelos, Eva M.
    Neven, Patrick
    Karlsson, Per
    Mueller, Bettina
    Jochum, Wolfram
    Zaman, Khalil
    Martino, Silvana
    Geyer, Charles E.
    Jerzak, Katarzyna J.
    Davidson, Nancy E.
    Coleman, Robert E.
    Ingle, James N.
    van Mackelenbergh, Marion T.
    Loi, Sherene
    Colleoni, Marco
    Schnabel, Catherine A.
    Treuner, Kai
    Regan, Meredith M.
    [J]. JAMA ONCOLOGY, 2024,